Potential role of targeted therapies in the treatment of triple-negative breast cancer

Breast cancer is the most common cancer type that affects women and is the major cause of morbidity and mortality. Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype and accounts for 10–20% of all breast cancer cases. TNBC is commonly characterized by the absence of estrogen...

Full description

Bibliographic Details
Main Authors: Jia, L., Shanmugam, M., Sethi, Gautam, Bishayee, A.
Format: Journal Article
Published: 2016
Online Access:http://hdl.handle.net/20.500.11937/7644
_version_ 1848745429139718144
author Jia, L.
Shanmugam, M.
Sethi, Gautam
Bishayee, A.
author_facet Jia, L.
Shanmugam, M.
Sethi, Gautam
Bishayee, A.
author_sort Jia, L.
building Curtin Institutional Repository
collection Online Access
description Breast cancer is the most common cancer type that affects women and is the major cause of morbidity and mortality. Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype and accounts for 10–20% of all breast cancer cases. TNBC is commonly characterized by the absence of estrogen, progesterone, and the Her2/neu receptor and is usually diagnosed by immunohistochemistry. Mutations in the BRCA1 gene, as well as overexpression of oncogenic kinases, such as human epidermal growth factor receptor 2, vascular endothelial growth factor-A, insulin-like growth factor-1 (IGF-1)/IGF-1 receptor, and transforming growth factor-β1, have been found to be correlated with a higher risk of metastasis and poor overall survival in TNBC patients. The current review briefly discusses the various treatment options including chemotherapeutics and targeted therapies that are available currently for the therapy of TNBC patients and highlights their comparative benefits and disadvantages for clinical application.
first_indexed 2025-11-14T06:17:13Z
format Journal Article
id curtin-20.500.11937-7644
institution Curtin University Malaysia
institution_category Local University
last_indexed 2025-11-14T06:17:13Z
publishDate 2016
recordtype eprints
repository_type Digital Repository
spelling curtin-20.500.11937-76442017-09-13T14:33:46Z Potential role of targeted therapies in the treatment of triple-negative breast cancer Jia, L. Shanmugam, M. Sethi, Gautam Bishayee, A. Breast cancer is the most common cancer type that affects women and is the major cause of morbidity and mortality. Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype and accounts for 10–20% of all breast cancer cases. TNBC is commonly characterized by the absence of estrogen, progesterone, and the Her2/neu receptor and is usually diagnosed by immunohistochemistry. Mutations in the BRCA1 gene, as well as overexpression of oncogenic kinases, such as human epidermal growth factor receptor 2, vascular endothelial growth factor-A, insulin-like growth factor-1 (IGF-1)/IGF-1 receptor, and transforming growth factor-β1, have been found to be correlated with a higher risk of metastasis and poor overall survival in TNBC patients. The current review briefly discusses the various treatment options including chemotherapeutics and targeted therapies that are available currently for the therapy of TNBC patients and highlights their comparative benefits and disadvantages for clinical application. 2016 Journal Article http://hdl.handle.net/20.500.11937/7644 10.1097/CAD.0000000000000328 restricted
spellingShingle Jia, L.
Shanmugam, M.
Sethi, Gautam
Bishayee, A.
Potential role of targeted therapies in the treatment of triple-negative breast cancer
title Potential role of targeted therapies in the treatment of triple-negative breast cancer
title_full Potential role of targeted therapies in the treatment of triple-negative breast cancer
title_fullStr Potential role of targeted therapies in the treatment of triple-negative breast cancer
title_full_unstemmed Potential role of targeted therapies in the treatment of triple-negative breast cancer
title_short Potential role of targeted therapies in the treatment of triple-negative breast cancer
title_sort potential role of targeted therapies in the treatment of triple-negative breast cancer
url http://hdl.handle.net/20.500.11937/7644